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Abstract 23 
Regression discontinuity (RD) is a quasi-experimental design that may provide valid 24 
estimates of treatment effects in case of continuous outcomes. We aimed to evaluate 25 
validity and precision in the RD design for dichotomous outcomes. 26 
We performed validation studies in three large RCTs (CRASH, GUSTO and 27 
PROSPER). To mimic the RD design, we selected patients above and below a cut-off 28 
(e.g. age 75 years) randomized to treatment and control respectively. Adjusted logistic 29 
regression models using restricted cubic splines (RCS) and polynomials, and local 30 
logistic regression models estimated the odds ratio (OR) for treatment, with 95% 31 
confidence intervals to indicate precision.  32 
In CRASH, treatment increased mortality with OR 1.22 [95% CI 1.06; 1.40] in the RCT. 33 
The RD estimates were 1.42 [0.94; 2.16] and 1.13 [0.90; 1.40] with RCS adjustment and 34 
local regression respectively. In GUSTO, treatment reduced mortality (OR 0.83 [0.72; 35 
0.95]), with more extreme estimates in the RD analysis (OR 0.57 [0.35; 0.92] and 0.67 36 
[0.51; 0.86] respectively). In PROSPER, similar RCT and RD estimates were found, 37 
again with less precision in RD designs.  38 
We conclude that the RD design provides similar but substantially less precise 39 
treatment effect estimates compared to an RCT, with local regression being the 40 
preferred method of analysis.  41 
 42 
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Abbreviations 48 
RD = Regression Discontinuity design 49 
RCT = Randomized Controlled Trial 50 
PROSPER = PROspective Study of Pravastatin in elderly individuals at risk of vascular 51 
disease 52 
CRASH = Corticosteroid Randomisation After Significant Head injury  53 
GUSTO = The Global Utilization of Streptokinase and Tissue plasminogen activator for 54 
Occluded coronary arteries  55 
CI = Confidence Interval 56 
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What is new? 70 
- RD design provides similar but substantially less precise treatment effect estimates compared to 71 
an RCT in dichotomous outcomes 72 
- local regression is the preferred method of analysis when using an RD design with dichotomous 73 
outcomes 74 
- global treatment effect estimates from RD designs should only be presented secondary to local 75 
average treatment effect estimates and never as the primary parameter of interest 76 
- a strength of this study is the use of data from three large RCTs to be able to compare the RD 77 
results with the RCT estimates and therefore we were able to carefully assess interaction 78 
between the assignment variable and treatment 79 
- our results suggest when there is no interaction between the assignment variable and treatment – 80 
and thus a global treatment effect can be estimated – the results from the RCS adjusted analyses 81 
and local logistic regression are more similar to each other than when there is interaction 82 
 83 
 84 
85 
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Introduction 86 
Randomized clinical trials (RCTs) provide the most reliable evidence of effectiveness of 87 
medical interventions.1 Nevertheless, recruitment of sufficient numbers of patients is a 88 
challenge in RCTs; it is estimated that less than 50% of the RCTs meet their recruitment 89 
targets.2,3 Patients’ treatment preferences and clinicians equipoise are often cited as 90 
barriers to recruitment in RCTs.2,4,5,6,7. Patients participating in trials may poorly 91 
represent the population of interest.8,9 Especially, under-representation of older 92 
participants and women is well known in RCTs.8,10  93 
The quasi-experimental “regression discontinuity” (RD) design is an alternative 94 
epidemiological design to assess effectiveness of treatment. It has been suggested that 95 
RD is the observational design that most resembles an RCT.11,12 In the RD design, 96 
treatment is not assigned randomly, but is allocated to a subset of patients, based on a 97 
baseline assignment variable, often related to the outcome. The control group consists 98 
of a complementary subset of patients, not receiving treatment. E.g. all patients with an 99 
age over 75 years receive treatment and patients with an age below 75 years do not 100 
receive treatment and are considered as the control group. Such treatment assignment 101 
method may closely resemble clinical practice and may thus facilitate patient inclusion. 102 
In the analysis of the treatment effect, a regression model is used to compare treatment 103 
to the control group, while adjusting for the treatment assignment variable, in this 104 
example age. 105 
The RD design is attractive because some of the challenges of the randomization 106 
process are avoided. However, the estimates from this quasi-experimental design may 107 
be substantially less efficient compared to an RCT.13 The validity of RD estimates on 108 
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continuous outcomes are well studied13,14,15, but the validity of the RD design with 109 
binary outcomes is less known. Only a few examples have been described before16,17, 110 
while many health outcomes are dichotomous. Moreover, the efficiency of modeling 111 
approaches is unclear, i.e. the precision of estimated treatment effects. The aim of this 112 
study was to assess validity and precision of the RD design in studies with dichotomous 113 
outcome compared to an RCT. We hereto analyzed data from three large RCTs. 114 
115 
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Methods 116 
Patients 117 
Three trials were used to validate the RD design in empirical data. To assess the 118 
internal validity of the RD design we compared RD estimates with the estimates 119 
resulting from the RCT data. For the RD design we used a continuous baseline variable 120 
as assignment variable and the dichotomous endpoints of the RCTs. 121 
The “Corticosteroid Randomisation After Significant Head injury” (CRASH) trial studied 122 
the effect of corticosteroids on death and disability after head injury.18 CRASH enrolled 123 
10,008 patients between 1999 and 2005. The primary outcome in CRASH was 14-day 124 
mortality.  We included 9,554 patients with complete outcome data of whom 2,323 died 125 
before 14 days (24%). The median age was 33 years (IQR: 23 – 47 years).  126 
Second, we analyzed 30,510 patients from “The Global Utilization of Streptokinase and 127 
Tissue plasminogen activator for Occluded coronary arteries” trial (GUSTO). Patients 128 
were entered between 1990 and 1993. 10,348 patients were assigned to treatment 129 
(accelerated tissue plasminogen activator, t-PA) and 20,162 patients were used as 130 
control patients receiving streptokinase.19 The primary outcome was 30-day mortality. 131 
The median age was 61 (IQR: 52 – 69) and mortality occurred in 2,128 (7%). For both 132 
CRASH and GUSTO, age was used as the treatment allocation variable. 133 
Third, we analyzed data from “PROspective Study of Pravastatin in elderly individuals at 134 
risk of vascular disease” (PROSPER).20 This study enrolled 5,804 patients between 135 
December 1997 and May 1999, who were assigned to pravastatin (n = 2,891) or 136 
placebo (n = 2,913) to reduce the risk of coronary disease in elderly individuals. The 137 
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outcome was a composite endpoint of coronary death, non-fatal myocardial infarction 138 
and fatal or non-fatal stroke at 3.2 years on average after randomization. 881 (15%) of 139 
the patients experienced the composite endpoint. The median total cholesterol level 140 
was 5.6 mmol/L (IQR: 5.0 – 6.3 mmol/L) at baseline (Table 1). For PROSPER, we 141 
considered baseline total cholesterol as the treatment allocation variable. 142 
 143 
Statistical analysis 144 
To analyze the data as an RD design, we selected those patients with a baseline value 145 
above the median of the assignment variable, who were assigned to treatment in the 146 
original RCT as the intervention group, and those with a baseline value below the 147 
median and not assigned to treatment in the RCT as control group. Histograms of the 148 
baseline assignment variables for each study were plotted, as well as binned 149 
scatterplots for outcome means for treated and controls at each baseline assignment 150 
value. The analysis was based on the intention-to-treat principle. This led to inclusion of 151 
approximately half of the RCT patients. The treatment effect was expressed as odds 152 
ratios (OR) with 95% confidence intervals (95% CI), with adjustment for the baseline 153 
variable in a logistic regression model. To compare the RD estimates to the RCT 154 
estimates in comparable sample sizes, random samples of 50% from the complete RCT 155 
data were drawn (5000 times). To compare the designs in terms of efficiency we 156 
calculated the ratio of variances between both designs based on estimated standard 157 
errors (SEs) of the estimated treatment effects: ( SE design 2 / SE design 1 ) 2 . 158 
Previous work has shown that the validity of the RD design is highly dependent on the 159 
quality of the adjustment in the analysis phase, and on assumptions of a local or global 160 
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effect of the treatment.13 All analyses (RCT and RD) were adjusted for the baseline 161 
variable that was used to attribute treatment; age in both CRASH and GUSTO and 162 
baseline cholesterol in the PROSPER trial. We assessed non-linearity of the effect of 163 
the baseline variable with non-linear restricted cubic splines (RCS) functions.  An RCS 164 
function is a smooth function that consists of pieced-together cubic splines that are 165 
restricted to be linear in the tails. We used three knots for adequate flexibility.21 166 
Consequently we used the RCS of the baseline variable in the adjustment model for 167 
optimal adjustment. To consider a different approach to estimate RD estimates, we also 168 
used polynomials of the baseline variables in the adjustment model. R2 statistics were 169 
calculated to indicate the explained variance of the adjustment model. 170 
The approach described above assumes a global treatment effect. It has been argued 171 
that this assumption is hard to make and can never be proven.11 We therefore also 172 
analyzed the RD design with local logistic regression models. In local logistic 173 
regression, only patients around the cut-off were used in the analysis to estimate the 174 
treatment effect. For the local estimations, the gam package in R was used, in which a 175 
default span of 0.5 is set. Gaussian kernel was used for the local logistic regression 176 
analysis. Using this kernel, the observations outside the span have lower influence on 177 
the estimation, but all the data are used in the analysis. To assess differential treatment 178 
effects, we studied interaction between the baseline variable and the treatment in the 179 
RCT data. For all three trials we assessed treatment effect heterogeneity in the 180 
complete RCT data, using interaction terms between treatment and the assignment 181 
variable.  Moreover, to study the stability of the estimates for all three validation studies, 182 
we added RD analyses on an additional cut-off.  183 
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All statistical analyses were performed in R statistical software version 2.15.3 (R 184 
Foundation for Statistical Computation, Vienna, Austria) using the rms and gam 185 
package.  186 
Results  187 
In CRASH the treatment was harmful. The adjusted OR was 1.22 [95% CI: 1.06; 1.40] 188 
for the effect of treatment on mortality in the 50% subset of the RCT. For the 189 
hypothetical RD design, the estimated OR was 1.42 [0.94; 2.16], with RCS adjustment 190 
for age. When analyzed with polynomial adjustment the OR for treatment was 1.09 191 
[0.81; 1.46]. The alternative method to analyze this hypothetical RD design, local logistic 192 
regression, resulted in an estimated OR of 1.13 [0.90; 1.40] (Table 2).  193 
In GUSTO the estimated OR for mortality was 0.83 [0.72; 0.95] in a subset of 50% of 194 
the patients. The estimated OR, in the RD scenario was 0.57 [0.35; 0.92] adjusted with 195 
RCS for age. The OR for treatment from RD estimated with polynomial adjustment for 196 
age was 0.82 [0.63; 1.07]. The analysis with local logistic regression resulted in an 197 
estimated OR of 0.67 [0.51; 0.86] (Table 3). 198 
In the PROSPER trial, the adjusted OR for the composite endpoint of coronary death, 199 
non-fatal myocardial infarction and fatal or non-fatal stroke was 0.85 [95% CI; 0.69; 200 
1.04] when assessed in the subset of 50% of the RCT. The estimated OR was 0.80 201 
[0.46; 1.38] in the hypothetical RD design adjusted for baseline cholesterol with RCS. 202 
The OR for treatment from RD estimated with polynomial adjustment for age was 0.81 203 
[0.56; 1.16]. The RD design analyzed with local logistic regression showed an OR for 204 
treatment of 0.79 [0.56; 1.13] (Table 4). 205 
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In none of the RCTs we found statistically significant interaction between treatment and 206 
the assignment variable. However, this interaction test has limited statistical power. In all 207 
three trials there appeared to be a differential treatment effect over the range of the 208 
assignment variable, (Figure 1d, 2d and 3d). This is confirmed in the additional RD 209 
analysis with treatment assignment based on a different cut-off (Table 2, 3 and 4). In 210 
these validation studies we see slightly different RD estimates between the two different 211 
assignment approaches in all three studies. 212 
In terms of efficiency, the RD with adjustment was 7.2 to 12.1 times less efficient than 213 
the adjusted RCT, compared to 3.1 to 4.5 less efficient estimates from RD with 214 
polynomial adjustment. The RD design analyzed with local logistic regression was 2.5 to 215 
3.5 times less efficient than the adjusted RCT (Table 5).  216 
 217 
 218 
 219 
 220 
 221 
 222 
 223 
 224 
 225 
 226 
 227 
 228 
Discussion 229 
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This validation study, with data from three large RCTs, showed that the treatment effect 230 
estimates from the hypothetical RD were similar to the treatment effect estimates from 231 
the RCTs, either with RCS and polynomial adjustment or local logistic regression. In all 232 
three studies the confidence interval of all RD estimates overlapped with the point 233 
estimate of the RCT. However, RD estimates were substantially less precise.  234 
 235 
Causality in regression discontinuity design 236 
The advantage of a quasi-experimental, prospective, RD design over an observational 237 
study is the controlled assignment of treatment. This property is shared with an RCT. As 238 
Labrecque et al. stated, in both an RCT as in an RD design, we have good knowledge 239 
of the assignment mechanism.11 In RCTs, treatment is randomly allocated and in RD 240 
treatment is assigned to patients using a baseline assignment variable. The treated and 241 
untreated patients in an RCT are unconditionally exchangeable. Therefore, RCTs are 242 
accepted to make causal inference. In an RD design the treated and the control patients 243 
are not exchangeable across the whole baseline range since they have a systematically 244 
different baseline characteristic. In RD the treated and untreated are only exchangeable 245 
close to the cut-off of the baseline assignment variable.11,12 Therefore, causal inference 246 
can only be made around the cut-off in an RD design, where patients can be considered 247 
to be exchangeable. The causal treatment effect estimated in RD is a local treatment 248 
effect estimate. This means that comparing estimates from RCT and RD may not be 249 
completely straightforward, even with comparable RCT and RD data.11 Therefor  it may 250 
not be entirely fair to interpret the concordance between local RD estimates and global 251 
RCT estimates as a measure of validity of RD estimates. The overall RCT estimate is 252 
 13
the average treatment effect in the whole RCT population, although we can condition on 253 
the assignment variable for more efficient analysis.22-25 An RD estimate is a local 254 
treatment effect among patients at the cut-off and may vary dependent on the cut-off 255 
chosen.13 At the end of the day, it is the RCT estimate that is the average of local 256 
estimates across the distribution of the assignment variable. 257 
 258 
Global vs. local treatment effects 259 
Only when treatment does not interact with the baseline assignment variable the 260 
estimate from an RD design can be interpreted as a global treatment effect estimate.11 261 
In order to estimate a global treatment effect estimate in RD, one would have to feel 262 
confident modeling the relationship between the assignment variable and the outcome 263 
even where it is not observed in the data.11,26,27 In other words, the model for the 264 
assignment variable–outcome relationship in both the treated and untreated groups 265 
would have to be extrapolated to the side of the cutoff where they were not observed.11  266 
When using RCS or polynomial adjustment, the treatment effect in CRASH was slightly 267 
different compared to the RCT. Graphical inspection showed qualitative interaction 268 
between treatment and the adjustment variable age (Figure 1d). At the cut-off (age 33 269 
years) the treatment effect – the difference between the plotted line for the control 270 
patients and the plotted line for the treated patients – was larger than the global RCT 271 
effect which is shown in Figure 1a. This explains the difference between the RD 272 
estimate and the RCT. The presence of a heterogeneous treatment effect over the 273 
range of age was confirmed in the RD analysis with treatment based on a different cut-274 
off, resulting in less similar treatment estimates compared to the RCT estimates. 275 
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Qualitative interaction was also observed in GUSTO (Figure 2d), and could have led to 276 
more extreme RD estimates (0.57 and 0.67) compared to the OR estimated in the RCT 277 
(0.83). At the cut-off of 62 years in Figure 2d a larger treatment effect is shown 278 
compared to the global treatment effect in Figure 2a. However, in RD with polynomial 279 
adjustment for age, the treatment effect is similar (0.82) to the RCT estimate. A smaller 280 
treatment effect was estimated when the cut-off for treatment assignment was set at 70 281 
years. This is also confirmed in Figure 2d; after the age of 62 the treatment effect 282 
decreases. 283 
In PROSPER, also qualitative interaction was found and shown in Figure 3d. However, 284 
RD with treatment assignment set at cholesterol 5.6 mmol/L, RD estimates (0.80, 0.81 285 
and 0.79) and the RCT estimate (0.85) were quite similar. When the treatment 286 
assignment rule was set at cholesterol 6.2 mmol/L for RD, the RD estimates were 287 
slightly different from the RCT estimate. These results confirm that the RD estimate is 288 
not equal to the global RCT treatment effect estimate when the treatment effect is 289 
heterogeneous across the baseline assignment variable.  290 
In a prospective RD design, it is hard to know whether the baseline assignment variable 291 
interacts with treatment. It can be formally tested but since the treatment groups each 292 
have data on only one side of the cut-off, the result only represents possible interaction 293 
at a small range of the assignment variable, around the cut-off.  Thus, the assumptions 294 
required to estimate the global treatment effect are not verifiable within the RD design. 295 
This is why it has been suggested that global treatment effect estimates from RD 296 
designs should only be presented secondary to local average treatment effect estimates 297 
and never as the primary parameter of interest.11,12  298 
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In this study we also assessed and compared RCS and polynomials for adjustment in 299 
RD. The advantage of an RCS function over polynomial adjustment is the restriction of 300 
the function to be linear in the tails. This is important when using this for optimal 301 
adjustment in for example RCTs, to estimate global effects over the whole range of the 302 
population studied. However, in RD we are primarily interested in local estimates and 303 
thus optimal adjustment around the cut-off for treatment assignment. So the advantage 304 
of RCS spline functions over polynomial adjustment in for example RCTs, may be less 305 
applicable to optimal adjustment in RD. 306 
Our results suggest when there is no interaction between the assignment variable and 307 
treatment – and thus a global treatment effect can be estimated – the results from the 308 
RCS and polynomial adjusted analyses and local logistic regression are more similar to 309 
each other than when there is interaction. If there was some interaction between the 310 
assignment variable and treatment, the results from local logistic regression and the 311 
RCS and polynomial adjusted analyses were less similar. So, the comparison of both 312 
RD estimates could be a way to have more information on the assignment variable – 313 
treatment relationship. 314 
 315 
Efficiency of RD design 316 
The RD estimates with adjustment appeared to be substantially less efficient than the 317 
RCT estimates. An RD design analyzed with adjusted logistic regression using RCS 318 
adjustment implies that 7.2 to 12.1 times more patients need to be included in the study 319 
compared to an RCT design. RD with polynomial adjustment would need 3.1 to 4.5 320 
more patients compared to an RCT. If one would analyze the RD design with local 321 
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logistic regression, this study would need about 2.4 to 3.6 times more patients than an 322 
RCT. So, the local regression approach was more efficient compared to the adjusted 323 
logistic regression. Also in terms of efficiency, local logistic regression would be 324 
preferred to analyze an RD design.   325 
In absolute numbers an RD design needs more patients to obtain similar efficiency, 326 
compared to an RCT to estimate global treatment effect estimates. Although RD is 327 
described as less efficient than RCT in identifying the global average causal effect, it 328 
may be nearly as good in identifying the local causal effect, which may be of interest 329 
depending on the context. From a power perspective, it would be a fair comparison if 330 
the RCTs were powered to estimate treatment effects in the assignment variable 331 
subgroups around the discontinuity and compare these with the local RD treatment 332 
effect estimates. However, in our study we focus on the comparison between global 333 
RCT estimates and estimates from an RD design, and the efficiency of an RD design to 334 
estimate global treatment effect estimates. 335 
Also, an RD design could facilitate patient recruitment, especially when the cut-off for 336 
treatment assignment closely resembles clinical practice. In these specific cases an RD 337 
design may be cheaper and less-time intensive than an RCT. Besides, RD designs 338 
could be conducted in different settings than RCTs; one can assume that RD design 339 
have less stringent inclusion criteria. This would be especially the case in a 340 
retrospective RD design when data from (clinical) registries are used. Therefore, some 341 
argue that data used in RD designs could lead to more external validity.28,29  342 
 343 
Linear versus logistic models in RD 344 
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In this study we specifically assess the performance of RD vs RCT in the context of 345 
dichotomous outcomes and logistic regression, which is not the standard in RD designs, 346 
but is common in health research. RD is underused with logistic regression models; only 347 
a few examples are described before.16,17 RD can be easily extended to generalized 348 
linear models like logistic regression.30 When using dichotomous endpoints in RD it is 349 
straightforward to obtain more interpretable parameters like risk differences and risk 350 
ratios even in the logistic regression context, because the predicted probabilities at the 351 
threshold can be obtained directly from the model. The only barrier using logistic models 352 
in RD would be the absence of a data driven optimal bandwidth selector for the logistic 353 
model, like Imbens-Kalyanamaran31 optimal bandwidth calculation is available for local 354 
linear regression models. For the local estimations in this study the gam package in R 355 
was used, in which a default span a 0.5 proportion of the observations over the 356 
assignment range is included. This can be adjusted specifying “span” in the gam 357 
function, for example span=0.2. When one is interested in a local treatment effect 358 
estimate, extending the span will in theory decrease validity but also increase reliability.   359 
  360 
Strengths and limitations 361 
We used RCT data to evaluate a hypothetical RD design, in which we artificially set the 362 
cut-off to “assign” treatment. This resulted in perfect adherence to the defined cut-off. 363 
This is unlikely to be the case in real life where which patients are prospectively 364 
assigned to treatment. A strength of this study is the use of data from three large RCTs 365 
to be able to compare the RD results with the RCT estimates. Moreover, because of the 366 
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RCT data we were able to carefully assess interaction between the assignment variable 367 
and treatment.  368 
 369 
Conclusion and recommendations 370 
Our findings for dichotomous outcomes are in line with previous work on RD for 371 
continuous outcomes.13 The RD design may provide similar treatment effect estimates 372 
compared to RCT estimates for dichotomous outcome measures, but has some strong 373 
disadvantages that should be carefully considered when choosing an RD design to 374 
assess the effectiveness of a medical intervention. First, to be able to estimate the 375 
same global treatment effect in an RD design as in an RCT, the assumption of a global 376 
treatment effect over the range of the assignment variable is required. In prospectively 377 
collected RD data this assumption of a global treatment effect cannot be proven. Global 378 
treatment effect estimates from RD designs should therefore only be reported 379 
secondary to local treatment effect estimates. Second, the RD design is substantially 380 
less efficient than an RCT, requiring sample sizes at least three times higher than for the 381 
conventional RCT to obtain the same precision for the treatment effect estimate. In this 382 
study we found local logistic regression would be most efficient to analyze an RD 383 
design. Future research on the RD design should focus on more efficient application of 384 
the RD design, considering different approaches to estimate treatment effects from an 385 
RD design and examining their properties. 386 
 387 
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Table 1. Patient characteristics of CRASH (n = 9554), GUSTO (n = 30,510) and PROSPER (n = 488 
5804).  489 
Characteristic CRASH GUSTO PROSPER 
N in treatment arm (%) 4800 (50) 10348 (34) 2891 (50) 
N in control arm (%) 4454 (50) 20162 (66) 2913 (50) 
Median (IQR) of baseline 
variable for treatment 
assignment* 
33 (23 - 47) 
years 
61 (52 – 69) 
years 
5.6 (5.0 – 6.3) 
mmol/L 
N outcome (%)** 2323 (24) 2128 (7) 881 (15) 
 490 
* Baseline measurement is age in years in CRASH and GUSTO and total cholesterol in mmol/L 491 
in PROSPER. 492 
** Outcome is 14-day all-cause mortality in CRASH, 30-day all-cause mortality in GUSTO and a 493 
composite endpoint of coronary death, non-fatal myocardial infarction and fatal or non-fatal 494 
stroke at 3.2 years on average in PROSPER. 495 
496 
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Table 2. RCT and RD analyses in the CRASH trial (n = 9554). 497 
Analysis N total R2 (%) 
OR (95% CI) for 14-
day mortality 
 
Standard error 
(SE) of treatment 
effect estimate 
 
RCT 
 
 
Linear* 
adjustment 4777  7 1.22 (1.06; 1.40) 0.071 
 
RD – assignment:  age ≤ 33 Tx-, age > 33 Tx+  
RCS* adjustment 4844  10 1.42 (0.94; 2.16) 0.212 
 
Polynomial* 
adjustment 
4844  10 1.09 (0.81; 1.46) 0.151 
 
Local logistic 
regression 
4844  NA 1.13 (0.90; 1.40) 0.112 
 
RD – assignment: age ≤ 40 Tx-, age > 40 Tx+  
RCS* adjustment 4806  10 1.04 (0.68; 1.60) 0.218 
 
Polynomial* 
adjustment 
4806  10 0.94 (0.72; 1.23) 0.138 
 
Local logistic 
regression 
4806  NA 1.02 (0.80; 1.32) 0.129 
 
*Linear, RCS or polynomial adjustment means that baseline age was used as a linear, RCS or polynomial 498 
term in the regression analysis to control for age. 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
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Table 3. RCT and RD analyses in the GUSTO trial (n = 30,510). 507 
Analysis N total R2 (%) 
OR (95% CI) for 
30-day mortality 
 
Standard error (SE) of 
treatment effect 
estimate 
RCT 
 
Linear* 
adjustment 15255 12 0.83 (0.72; 0.95) 0.071 
RD – assignment:  age ≤ 62 Tx-, age > 62 Tx+ 
RCS* 
adjustment 
15423 11 0.57 (0.35; 0.92) 0.246 
Polynomial* 
adjustment 
15423 11 0.82 (0.63; 1.07) 0.133 
Local logistic 
regression 
15423 NA 0.67 (0.51; 0.86) 0.132 
RD – assignment: age ≤ 70 Tx-, age > 70 Tx+ 
RCS* 
adjustment 
17846  10 0.94 (0.72; 1.22) 0.133 
Polynomial* 
adjustment 
17846  10 0.95 (0.75; 1.21) 0.121 
Local logistic 
regression 
17846  NA 0.90 (0.74; 1.10) 0.102 
*Linear, RCS or polynomial adjustment means that baseline age was used as a linear, RCS or polynomial 508 
term in the regression analysis to control for age. 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
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Table 4. RCT and RD analyses in the PROSPER trial (n = 5804). 517 
Analysis N total R2 (%) 
OR (95% CI) for 
composite endpoint 
 
Standard error (SE) of 
treatment effect estimate 
RCT 
 
Linear 
adjustment 2902 0.4 0.85 (0.69; 1.04) 0.104 
RD – assignment: cholesterol ≤ 5.6 Tx-, cholesterol > 5.6 Tx+ 
RCS adjustment 2919 0.7 0.80 (0.46; 1.38) 0.279 
Polynomial 
adjustment 
2919 0.7 0.81 (0.56; 1.16) 0.185 
Local logistic 
regression 
2919 NA 0.79 (0.56; 1.13) 0.181 
RD – assignment: cholesterol ≤ 6.2 Tx-, cholesterol > 6.2 Tx+ 
RCS adjustment  2969 0.7 1.30 (0.71; 2.40) 0.311 
Polynomial 
adjustment 
 2969 0.6 1.03 (0.69; 1.53) 0.205 
Local logistic 
regression 
 2969 NA 1.07 (0.75; 1.56) 0.187 
*Linear, RCS or polynomial adjustment means that baseline cholesterol level was used as a linear, RCS 518 
or polynomial term in the regression analysis to control for cholesterol level. 519 
 520 
 521 
 522 
 523 
 524 
 525 
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Table 5. Relative efficiency in terms of required sample size for different designs in 527 
CRASH, GUSTO and PROSPER*. 528 
 CRASH GUSTO PROSPER 
RCT adjusted vs RD RCS 
adjustment 8.9 12.1 7.2 
RCT adjusted vs RD polynomial 
adjustment 4.5 3.5 3.1 
RCT adjusted vs RD local logistic 
regression 2.5 3.5 3.0 
 529 
*Formula: (SE design 2 / SE design 1) 2 530 
531 
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Figure 1. CRASH 532 
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a Linear function of the baseline variable over the outcome variable in RCT data. The space between 538 
both lines indicates the main treatment effect in the RCT. 539 
b Linear interaction function of the treatment effect over the baseline variable in RCT data. 540 
c Linear function of the baseline variable over the outcome variable in RD design. The space between 541 
both lines at the cut-off value indicates the treatment effect in the RD design. 542 
d RCS interaction function of the treatment effect over the baseline variable in RCT data. 543 
e RCS function of the baseline variable over the outcome variable in RD design. The space between both 544 
lines at the cut-off value indicates the treatment effect in the RD design. 545 
 546 
 547 
548 
 29
Figure 2. GUSTO 549 
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a Linear function of the baseline variable over the outcome variable in RCT data. The space between 555 
both lines indicates the main treatment effect in the RCT. 556 
b Linear interaction function of the treatment effect over the baseline variable in RCT data. 557 
c Linear function of the baseline variable over the outcome variable in RD design. The space between 558 
both lines at the cut-off value indicates the treatment effect in the RD design. 559 
d RCS interaction function of the treatment effect over the baseline variable in RCT data. 560 
e RCS function of the baseline variable over the outcome variable in RD design. The space between both 561 
lines at the cut-off value indicates the treatment effect in the RD design. 562 
 563 
564 
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Figure 3. PROSPER 565 
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a Linear function of the baseline variable over the outcome variable in RCT data. The space between 570 
both lines indicates the main treatment effect in the RCT. 571 
b Linear interaction function of the treatment effect over the baseline variable in RCT data. 572 
c Linear function of the baseline variable over the outcome variable in RD design. The space between 573 
both lines at the cut-off value indicates the treatment effect in the RD design. 574 
d RCS interaction function of the treatment effect over the baseline variable in RCT data. 575 
e RCS function of the baseline variable over the outcome variable in RD design. The space between both 576 
lines at the cut-off value indicates the treatment effect in the RD design. 577 
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Supplement 1.  598 
a. Distribution of baseline age in years in CRASH. 599 
 600 
b. Distribution of baseline age in years in GUSTO.601 
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c. Distribution baseline cholesterol level in mmol/L in PROSPER. 604 
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Supplement 2. 619 
a. Binned scatterplot for mortality average, over the baseline age range in CRASH. 620 
 621 
 622 
 623 
 624 
 625 
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b. Binned scatterplot for mortality average, over the baseline age range in the GUSTO. 627 
 628 
 629 
 630 
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c. Binned scatterplot for composite endpoint average, over the baseline cholesterol level in 635 
mmol/L range in PROSPER. 636 
 637 
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